Delivered as Hybrid Event from 30 Oct - 1 Nov 2023
Live In-Person Conference Delivered 30 Oct -1 NovAmsterdamkeyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
Day 2: Main Conference
search
Day 2: Main Conference
search
07:30 - 08:0030 mins
Morning Spotlight Presentation
Enzyme Development for siRNA Production by Fragment Condensation
- Yusuke Hagiwara, PhD - Senior Scientist, Ajinomoto Bio-Pharma Services
08:10 - 08:155 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- Mike Webb, Ph.D. - Principal, MikeWebbPharma Ltd
08:10 - 08:155 mins
Peptide Discovery, Preclinical and Clinical
Chairperson's Remarks
- Christian Becker - Professor and Head of the Institute of Biological, University of Vienna
08:10 - 08:155 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
Chairperson's Remarks
- Mimoun Ayoub, Ph.D. - Vice President, Global Head Sales and Key Account Management, CordenPharma International
08:15 - 08:4530 mins
Oligonucleotide Chemistry, Manufacturing and Controls
European Update on CMC Requirements for Oligonucleotides
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
08:15 - 08:4530 mins
Peptide Discovery, Preclinical and Clinical
Chemical Space Guided Design of Peptide Drugs
- Clemence Delalande, PhD - Senior Scientist, GDBspace AG
08:15 - 08:4530 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
Endosomal Escape Vehicle (EEV) Platform to Enhance the Functional Delivery of Oligonucleotides
- Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
08:45 - 09:1530 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Development of Kilogram-Scale Convergent Liquid-Phase Synthesis of Oligonucleotides
- Xuan Zhou, PhD - Senior Scientist, Oligonucleotide Development, Biogen
08:45 - 09:1530 mins
Peptide Discovery, Preclinical and Clinical
The streaMLine Platform for Accelerated Peptide Clinical Candidate Identification
- Kristoffer Rigbolt, PhD - Chief Technology Officer, Gubra
08:45 - 09:1530 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
EDO Peptide Delivery of Exon 51 Skipping Oligonucleotide in Healthy Volunteers
- James McArthur, PhD - CEO and President, PepGen
09:15 - 09:4530 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Growing Pains: The Challenges of Long Oligonucleotide Synthesis
- Fred Briones, PhD - Director, Chemistry, Tessera Therapeutics
09:15 - 09:4530 mins
Peptide Discovery, Preclinical and Clinical
Therapeutic Targeting of Hdm2/HmX E3 Ligase in Cancer Cells with De Novo Cyclotides
- Julio Camarero, PhD - Professor, Pharmacology and Pharmaceutical Science, University of Southern California
09:15 - 09:4530 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
Overcoming Challenges To RNA Systemic Extrahepatic Delivery and Endosomal Escape With Peptide-Nucleotide Polyplexes
- Covadonga Paneda, PhD - Chief Development Officer, Altamira Therapeutics
09:45 - 10:3045 mins
Networking Refreshment Break in Poster and Exhibit Hall
10:30 - 11:0030 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Novel Thiomorpholino Oligonucleotides (TMOs) As a Robust Next Generation Platform for Splice Switching Antisense Therapies
- Rakesh Veedu, PhD - Associate Professor and Head, Precision Nucleic Acid Therapeutics Group, Murdoch University
10:30 - 11:0030 mins
Peptide Discovery, Preclinical and Clinical
Novel Chemistry Platform Technologies for Creating Next-generation Precision Immunotherapies
- Vijaya Pattabiraman, PhD - Co-founder and CTO, Bright Peak Therapeutics
10:30 - 11:0030 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
Use of Next Generation AAVs to Target Specific Cell types in the CNS or Nanoparticles to Enhance Drug delivery into the CNS
- Robert Bowser PhD - Chief Scientific Officer, Barrow Neurological Institute
11:00 - 11:3030 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Refractive Index as a PAT Tool to Monitor Solid Phase Oligonucleotide Synthesis
- John Lopez, PhD - Senior Expert Science & Technology, Novartis AG
11:00 - 11:3030 mins
Peptide Discovery, Preclinical and Clinical
Development of the B Cell Cancer Vaccine HER-Vaxx for the Treatment of Her-2 Expressing Cancers
- Nicholas Ede, PhD - Chief Technology Officer, Imugene
11:00 - 11:3030 mins
Delivery Strategies for Oligonucleotides, Peptides and mRNA
Bicyclic Peptide Transferrin Receptor 1 Ligands Conjugated to Oligonucleotide Therapeutics Improve Potency in Skeletal and Cardiac Muscle
- Brooke Anderson, PhD - Principal Scientist, Ionis Pharmaceuticals
11:35 - 12:0530 mins
Spotlight Presentation 1
Synthetic Oligonucleotides Aren’t Perfect: bioZen Oligo, Paired with HRMS, Elucidates What You’re Missing
- Michael McGinley - Director Global Applications, Phenomenex
11:35 - 12:0530 mins
Spotlight Presentation 2
Empowering Productivity with Pharma 4.0™
- Stefan Hyde - Automation Manager, Asahi Kasei Bioprocess America
11:35 - 12:0530 mins
Spotlight Presentation 3
Peptides as Biopharmaceuticals - Challenges in Biophysical Analysis
- Anshuman Shukla - Technical Expert, Intertek Pharmaceutical Services
12:05 - 13:2580 mins
Networking Luncheon in Poster and Exhibit Hall
13:25 - 13:5530 mins
Spotlight Presentation 1
Purification and Analysis of Exceptional Oligos – A Case Study
- Jonas Wege - Application Specialist, Tosoh Bioscience
13:25 - 13:5530 mins
Spotlight Presentation 2
Towards Unlocking Potential of Gene Therapy via applying Small Molecule Manufacturing Know-how and Technology
- Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
13:25 - 13:5530 mins
Spotlight Presentation 3
Developing Intuitive Software for Oligonucleotide Synthesis
- Daniel Oman - Senior System Engineer, Cytiva
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairperson's Remarks
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
13:55 - 14:005 mins
Peptide Discovery, Preclinical and Clinical
Chairman's Remarks
- Gavin Bennett, PhD - Senior Director, Drug Development, Bicycle Therapeutics Ltd
13:55 - 14:005 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
Chairperson Remarks
- Mimoun Ayoub, Ph.D. - Vice President, Global Head Sales and Key Account Management, CordenPharma International
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Supply Chain Constraints in the Oligonucleotide Market
- Asmara Agha - Director, Strategic Sourcing, Nitto Avecia
14:00 - 14:3030 mins
Peptide Discovery, Preclinical and Clinical
Resetting the Immune System without Shutting it Down
- Roly Foulkes, PhD - Chief Scientific Officer, Revolo Biotherapeutics
14:00 - 14:3030 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
Considerations for Scaling Lipid Based Parenteral Nanomedicines
- Michael Parr, PhD - Director of Formulation and Process Development, Evonik
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Sequence Confirmation of Long Oligonucleotides: Mass Spectrometric Investigations
- Michael Ruehl, PhD - Head of Quality Control Lab, BioSpring GmbH
14:30 - 15:0030 mins
Peptide Discovery, Preclinical and Clinical
The Manufacture of Peptides for Clinical Development
- Steven McIntyre - Peptide Process Development Department Manager, Almac Group
14:30 - 15:0030 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
Guiding mRNA-LNP Drug Products from Early R&D Programs to the Market – Scale Up and Production of mRNA LNPs
- Andreas Wagner - Head of Liposome Technology, Polymun Scientific GmbH
15:00 - 15:3030 mins
Oligonucleotide Chemistry Manufacturing and Controls
Breaking the Barrier to Long, High Purity Synthetic DNA
- J. William Efcavitch, PhD - Co-Founder & Chief Scientific Officer, Molecular Assemblies
15:00 - 15:3030 mins
Peptide Discovery Preclinical and Clinical
Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein in solid lesions
- Samuele Cazzamalli, Ph.D. - Head of Small Molecule Therapeutics, Philochem Ag
15:00 - 15:3030 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
Supporting mRNA-LNP Drug Products from Early R&D Programs to the Market – Scale Up and Production of mRNA Key Lipids
- Matthieu Giraud, Ph.D. - Global Director Peptide, Lipids and Carbohydrates Platforms, CordenPharma International
15:30 - 16:0030 mins
Networking Refreshment Break in Poster and Exhibit Hall
16:00 - 16:3030 mins
Oligonucleotide Chemistry Manufacturing and Controls
High-efficiency Nucleic Acid Manufacturing Systems to Fulfil the Promise of Genomic Medicine
- Helge Zieler, PhD - Founder & President, Primordial Genetics
16:00 - 16:3030 mins
Peptide Discovery Preclinical and Clinical
Bicycle Conjugates to Target Solid Tumors
- Gavin Bennett, PhD - Senior Director, Drug Development, Bicycle Therapeutics Ltd
16:00 - 16:3030 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
mRNA-LNP Manufacturing Technologies – A Pilot Study Through a Microfluidic Approach
- Umberto Romeo - Head of R&D, Corden Pharma Caponago
16:30 - 17:0030 mins
Oligonucleotide Chemistry Manufacturing and Controls
Technology for Biocatalytic Synthesis of Oligonucleotides
- Jill Caswell, PhD - Biology Team Leader, Almac Sciences
16:30 - 17:0030 mins
Peptide Discovery Preclinical and Clinical
Late Speaker Cancellation. Choose Another Track
16:30 - 17:0030 mins
Delivery Strategies for Oligonucleotides Peptides and mRNA
Targeted Delivery of Therapeutic Oligonucleotides to Muscles and CNS
- Guillaume Jacquot, PharmD, Ph.D - Translational Research Manager, Vect-Horus
17:00 - 18:0060 mins
Panel Discussion with Drinks and Snacks: DIVERSITY, EQUITY & INCLUSION IN THE SCIENTIFIC COMMUNITY
- Asmara Agha - Director, Strategic Sourcing, Nitto Avecia
- Cyndi Moyo - Founder, Tidalbase and Founder, Lean In Vienna Chapter
- Mike Webb, Ph.D. - Principal, MikeWebbPharma Ltd
- Helge Zieler, PhD - Founder & President, Primordial Genetics
- Beth Morgan - Head of Biopharma and Chemistries Business Development EMEAI, Agilent Technologies
18:00 - 18:055 mins
Close of Day Two
Get the Latest Event Updates
Sign up to get the latest event updates and information.